Abstract
The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.
Keywords: Anaplastic thyroid cancer, targeted molecular therapies, tyrosine kinase inhibitors, aurora kinase inhibitors, RET, BRAF, VEGFR, V600E, TKIs, peroxisome proliferator-activated receptor-, &, γ
Current Genomics
Title: New Targeted Therapies for Thyroid Cancer
Volume: 12 Issue: 8
Author(s): Alessandro Antonelli, Poupak Fallahi, Silvia M. Ferrari, Ilaria Ruffilli, Francesca Santini, Michele Minuto, David Galleri and Paolo Miccoli
Affiliation:
Keywords: Anaplastic thyroid cancer, targeted molecular therapies, tyrosine kinase inhibitors, aurora kinase inhibitors, RET, BRAF, VEGFR, V600E, TKIs, peroxisome proliferator-activated receptor-, &, γ
Abstract: The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.
Export Options
About this article
Cite this article as:
Antonelli Alessandro, Fallahi Poupak, M. Ferrari Silvia, Ruffilli Ilaria, Santini Francesca, Minuto Michele, Galleri David and Miccoli Paolo, New Targeted Therapies for Thyroid Cancer, Current Genomics 2011; 12 (8) . https://dx.doi.org/10.2174/138920211798120808
DOI https://dx.doi.org/10.2174/138920211798120808 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 4
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Preclinical Evaluation of In-111 and Ga-68 Labelled Minigastrin Analogues for CCK-2 Receptor Imaging
Current Radiopharmaceuticals Metastatic Thyroid Cancer Unresponsive to Conventional Therapies: Novel Management Approaches Through Translational Clinical Research
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Subject Index to Volume 4
Current Cancer Drug Targets ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Syntheses and Preliminary Evaluation of Dual Target PET Probe [<sup>18</sup>F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry Monoclonal Antibodies in the Treatment of Hematologic Malignancies: Radiation Dosimetry Aspects
Current Pharmaceutical Biotechnology Editorial [Hot Topic:Cross-Talk Between Endogenous Compounds and Regulatory Pathways of Drug Metabolism Guest Editor: Zdenek Dvorak]
Current Drug Metabolism Preface [ Endocrine and Metabolic Agents (Executive Editors: A.S. Wagman and W.L. Cody)]
Current Pharmaceutical Design Current Review of Small Molecule Ret Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Role of Phytochemicals in the Prevention of Menopausal Bone Loss: Evidence from In Vitro and In Vivo, Human Interventional and Pharmacokinetic Studies
Current Medicinal Chemistry New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiases
Current Medicinal Chemistry Lentisk (<i>Pistacia lentiscus L.</i>) a Renewable Source of Pure Shikimic Acid and its Antioxidant Activity
Current Bioactive Compounds The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Telomerase-Dependent Gene Therapy
Current Molecular Medicine